Dunvegan Associates’s AbbVie ABBV Stock Holding History

Dunvegan Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$39K	Hold	660	–	–	0.05%	107
2015 Q3	$36K	Hold	660	–	–	0.04%	108
2015 Q2	$44K	Sell	660 -150	-19%	-$9.79K	0.05%	102
2015 Q1	$47K	Hold	810	–	–	0.04%	113
2014 Q4	$53K	Hold	810	–	–	0.05%	104
2014 Q3	$47K	Hold	810	–	–	0.04%	103
2014 Q2	$46K	Hold	810	–	–	0.04%	108
2014 Q1	$42K	Buy	+810	New	+$40.9K	0.04%	110

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dunvegan Associates's ABBV Position: Q4 2015 in Review

Dunvegan Associates held its AbbVie (ABBV) position steady in Q4 2015 at 660 shares worth $39K. The position accounts for 0.05% of the portfolio, ranked #107.

Dunvegan Associates first reported a position in ABBV in Q1 2014 and has held it in 8 quarters since. The position peaked at $53K in Q4 2014. 1,637 funds tracked by Wall St. Rank hold ABBV as of Q4 2015.

Dunvegan Associates held 660 shares of AbbVie worth $39K as of Q4 2015.
Dunvegan Associates left its AbbVie share count unchanged in Q4 2015.
AbbVie made up 0.05% of Dunvegan Associates's portfolio in Q4 2015, its #107 holding.
Dunvegan Associates first reported a position in AbbVie in Q1 2014 and has held it in 8 quarters since.
Dunvegan Associates's AbbVie position peaked at $53K in Q4 2014.
1,637 funds tracked by Wall St. Rank held AbbVie as of Q4 2015.

Based on Dunvegan Associates's 13F filing for Q4 2015, filed 28 Apr 2017.